2F5
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more
2F5 (2F5) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.108x
Based on the latest financial reports, 2F5 (2F5) has a cash flow conversion efficiency ratio of -0.108x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.08 Million) by net assets (€9.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
2F5 - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how 2F5's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
2F5 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 2F5 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hacisco JSC
VN:HAS
|
N/A |
|
RENFORTH RESS. INC. NEW
F:9RR
|
N/A |
|
Manydev Studio SE
WAR:MAN
|
0.014x |
|
Evolving Systems Inc
PINK:EVOL
|
0.004x |
|
Star Vault AB (publ)
PINK:SRVTF
|
0.075x |
|
TVD Holdings PCL
BK:TVDH
|
-0.013x |
|
Aruma Resources Ltd
AU:AAJ
|
-0.265x |
|
Acticor Biotech SAS
PA:ALACT
|
1.026x |
Annual Cash Flow Conversion Efficiency for 2F5 (2021–2024)
The table below shows the annual cash flow conversion efficiency of 2F5 from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €9.98 Million | €-6.33 Million | -0.635x | -130.92% |
| 2023-12-31 | €-4.57 Million | €-9.38 Million | 2.053x | -50.25% |
| 2022-12-31 | €-1.76 Million | €-7.26 Million | 4.128x | +154.59% |
| 2021-12-31 | €982.00K | €-7.43 Million | -7.562x | -- |